Clinical Trial Update: VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating VX-710 in combination with doxorubicin and vincristine for recurrent small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• VX-710
• Vincristine (vincristine)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Lung Cancer | Phase 2 | Status: TERMINATED